Kezar Life Sciences

Historical price data

Kezar Life Sciences focuses on advancing unique protein-targeting approaches to address limitations of current treatments for chronic diseases, particularly autoimmune conditions and liver disease. The company's core technology platform includes selective immunoproteasome inhibition and Sec61 pathway targeting, designed to modulate immune function rather than cause direct immunosuppression. With its lead candidate zetomipzomib in clinical development for autoimmune hepatitis and other programs in earlier stages, Kezar aims to establish new therapeutic pathways for improved patient outcomes. The company maintains an active clinical development program and regularly reports financial results as a publicly traded entity.

Selective immunoproteasome inhibition and Sec61 pathway targeting using first-in-class small molecules designed to modulate immune function and regulate cellular protein homeostasis.

7 drugs in pipeline

Competes in autoimmune disease space against traditional immunosuppressants and emerging biologics. Differentiation through selective immunoproteasome inhibition aiming for immune modulation without broad immunosuppression. Limited direct competition in selective immunoproteasome inhibitor category.